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ABSTRACT 
Objective: The aim of the present study was to determine the effect of chlorophyllin (CHL) on hyperglycemia and hyperlipidemia in streptozotocin 
(STZ) induced diabetic mice. 
Methods: Diabetes was induced in mice by administering 150 mg/kg body weight (bw) dose of STZ. The effect of 10, 25, 50 and 100 mg/kg bw 
doses of CHL on hyperglycemia was examined in diabetic mice for the acute and sub-acute period. The intraperitoneal glucose tolerance test 
(IPGTT) was performed in diabetic (Group A) as well as diabetic treated with CHL (Group B), metformin (Group C), glibenclamide (Group D), and 
insulin (Group E) groups. The percent glycosylated hemoglobin (GHb%) level, lipid profile, and atherogenic index (AI) were determined in normal 
(Group A), diabetic (Group B) as well as diabetic treated with CHL (Group C), and metformin (Group D) groups. 
Results: In both acute and sub-acute antihyperglycemic study, 50 mg/kg bw dose of CHL was found effective in reduction of blood glucose level 
significantly and considered as an optimum dose. In IPGTT, the significant reduction of blood glucose level in Group B was observed at 2 h (h) and 4 
h in comparison with Group A. The GHb%, lipid profile and AI value of Group C were found significantly different from Group B in the study.  
Conclusion: The present study justifies the antihyperglycemic and antihyperlipidemic effects of CHL in STZ induced diabetic mice, hence suggesting 
its beneficial effect in the treatment of diabetes.  
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INTRODUCTION 
Diabetes mellitus (DM) is a serious global health issue with 415 
million assessed populace under diabetes grip worldwide in 2015 
and this fig. might ascend to 642 million by 2040 [1]. It’s also a 
serious matter of concern that India holds the second position after 
China with 69.2 million diabetic population in 2015 amongst all 
nations and evaluated to be 123.5 million by 2040 [1].  
DM is a metabolic disorder with heterogeneous etiology 
characterized by chronic hyperglycemia and deficiency of insulin 
secretion, insulin action or both that result in disturbances of 
carbohydrate, fat, and protein metabolism [2]. DM can be divided 
primarily into Type 1 or insulin dependent diabetes mellitus (IDDM) 
and Type 2 or non-insulin dependent diabetes mellitus (NIDDM). In 
both sorts of DM, prolonged hyperglycemia causes symptoms like 
polyuria, polydipsia, and various complications including 
retinopathy, nephropathy, and neuropathy [3, 4].  
Insulin deficiency has been known to cause lipolysis in adipose 
tissue and inactivation of lipoprotein lipase that prompts 
hyperlipidemia. Hyperlipidemia is one of the major factors in the 
development of micro and macrovascular complications of diabetes 
which causes morbidity and death [5].  
Chlorophyllin is a water-soluble, sodium-copper salt of the chlorophyll 
molecule. It has been well proved that CHL exhibits highly potent 
antioxidative activity under different oxidative stress conditions such 
as radiation and photosensitization induced oxidative damage [6-9]. 
However, many plants derived chemical compounds with antioxidant 
activity have been using therapeutically due to their ability to cure free 
radicals induced oxidative stress and diabetic complications. Recently, 
a search for appropriate antihyperglycemic and antihyperlipidemic 
agents has focused on plants used in traditional medicine because 
natural as well as semi-synthetic products may be a better option than 
currently used drugs. Therefore, the present work has been 
undertaken to ascertain the effect of CHL as antioxidant on 
hyperglycemia and hyperlipidemia in STZ induced diabetic mice. 
MATERIALS AND METHODS 
Chemicals 
CHL, STZ, and Metformin were procured from Sigma-Aldrich Co. (St. 
Louis, MO, USA.). Glibenclamide was purchased from Emcure 
Pharmaceuticals Ltd. (Pune, India). Insulin was purchased from Gland 
Pharma Ltd. (Hyderabad, India). Glycosylated hemoglobin kit obtained 
from Medsource Ozone Bio-medicals Pvt. Ltd. (Faridabad, India). Total 
Cholesterol, triglyceride, and HDL kits were procured from Coral Bio-
systems (Goa, India). The other chemicals used were of analytical 
grade procured from Merck Co. (Mumbai, India), Sisco Research 
Laboratories (Mumbai, India), and Himedia (Mumbai, India). 
Animals  
Healthy male swiss albino mice (Balb/C strain), weighing 25–30 g, 
were used for the study. All the experiments were carried out in 
accordance with the Institutional Ethics Committee (IEC) guidelines. 
Mice were housed in a room maintained at temperature 22 °C on a 
12 h light/dark cycle. They were provided a standard laboratory 
feed and water ad libitum.  
Induction of diabetes mellitus 
Diabetes was induced by a single high dose of STZ. After overnight 
fasting, mice were administered 150 mg/kg bw dose of STZ 
intraperitoneally (i. p.) i.e. prepared in ice-cold citrate buffer (0.1 M, 
pH 4.5). After STZ dose, mice had free access to food and 5% glucose 
solution overnight to counter the hypoglycemic shock [10]. The 
fasting blood glucose (FBG) level was checked with SD Check 
glucometer (SD Biosensor Inc., Korea) on the 3rd day after STZ 
injection. Mice with blood glucose level ≥ 200 mg/dl were selected 
and used for the experiments. 
Antihyperglycemic study 
Diabetic mice were divided into five different groups to carry out 
acute and sub-acute antihyperglycemic study. 
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Group A: Diabetic Control, administered only the distilled water. 
Group B: administered the 10 mg/kg bw dose of CHL. 
Group C: administered the 25 mg/kg bw dose of CHL. 
Group D: administered the 50 mg/kg bw dose of CHL. 
Group E: administered the 100 mg/kg bw dose of CHL. 
For acute study, doses were injected i. p. to overnight starved mice 
of respective groups and FBG level was checked at 0.5 h, 1 h, 2 h, 4 h, 
and 6 h after injection. While in the sub-acute study, doses were 
injected i. p. on every alternate day for up to 28 d (d) and FBG level 
was checked on 1 d, 7 d, 14 d, 21 d, and 28 d respectively. 
Intraperitoneal glucose tolerance test (IPGTT) 
The IPGTT was carried out into five different groups of diabetic mice 
and they were starved overnight before the experiment.  
Group A: Diabetic Control, administered only the distilled water. 
Group B: administered the 50 mg/kg bw dose of CHL. 
Group C: administered the metformin. 
Group D: administered the glibenclamide. 
Group E: administered the insulin. 
The reference drugs insulin, glibenclamide, and metformin were 
administered as described by Syiem et al. prior to the glucose load (2 
g/kg bw) [11]. The FBG level was measured before and 
subsequently at 0.5 h, 1 h, 2 h, and 4 h after the glucose load. From 
blood glucose versus time plot, the area under the glucose tolerance 
curve [AUGTC (t0–t4)] was calculated using the trapezoidal method.  
Biochemical analysis 
For biochemical analysis, four different groups of mice were selected 
and doses were injected i. p. on every alternate day for 28 d.  
Group A: Normal Control, administered only the distilled water. 
Group B: Diabetic Control, administered only the distilled water. 
Group C: Diabetic mice were administered the 50 mg/kg bw dose of CHL. 
Group D: Diabetic mice were administered the 50 mg/kg bw dose of 
metformin. 
At the end of the study, blood was collected from retro-orbital sinus 
under anesthesia. The GHb% level was estimated in blood using 
cation exchange method’s kit [12, 13]. The GHb% is the ratio of 
absorbance of glycosylated hemoglobin fraction and total 
hemoglobin fraction. Serum was prepared for lipid profile test 
according to the protocol described by Gasting et al. [14]. In lipid 
profile test, total cholesterol, HDL-C, and triglyceride levels were 
estimated using CHOD/PAP method, PEG/CHOD–PAP method, and 
GPO/PAP method’s kit respectively. The LDL-C and VLDL-C levels 
were calculated using the following formula [15].  
VLDL-C = Triglycerides/5 
LDL-C = Total cholesterol–(HDL-C+VLDL-C) 
AI value was calculated according to the following formula 
mentioned by Malaspina et al. to determine the cardiac risk in 
experimental groups [16]. 
AI = Total Cholesterol/HDL-C 
Statistical analysis 
Results are expressed as mean±SEM for six mice in each group. One-
way analysis of variance (ANOVA) followed by Tukey’s post hoc test 
was performed to compare differences between experimental 
groups using the statistical package “IBM SPSS Statistics 19.0 for 
Windows.” Statistical significance was set at p<0.05. 
RESULTS 
Antihyperglycemic study 
The result of the acute study of CHL is depicted by fig. 1. There was no 
significant reduction of FBG level in Group B whereas Group C showed 
significant reduction of FBG only at (324±20.92) 6 h in comparison 
with the Group A. The FBG level was reduced significantly at 
(354±12.81) 2 h, (312±24.60) 4 h, and (311±23.10) 6 h in Group D and 
(362±10.85) 1 h, (349±11.73) 2 h, (308±18.71) 4 h, and (303±11.86) 6 
h in Group E as compared with the Group A in the study.  
The result of the sub-acute study of CHL is depicted by fig. 2. The 
FBG level was reduced significantly only on 28 d in (321±14.87) 
Group B and (318±11.58) Group C as compared with the Group A. 
The Group D exhibited significant reduction of FBG level on 
(404±5.89) 14 d, (340±7.91) 21 d, and (221±11.22) 28 d and Group 
E exhibited significant reduction of FBG level on (416±2.73) 7 d, 
(387±5.39) 14 d, (332±7.52) 21 d, and (213±4.21) 28 d in 
comparison with the Group A in the study. 
 
 
Fig. 1: The acute antihyperglycemic study showing changes of 
FBG level in different experimental groups. The values 
represent the mean±SEM; n = 6. Significant difference: *p<0.05, 
**p<0.01 as compared with the group A 
 
 
Fig. 2: The sub-acute antihyperglycemic study showing changes of 
FBG level in different experimental groups. The values represent 
the mean±SEM; n = 6. Significant differences: *p<0.05, **p<0.01 
and ***p<0.001 as compared with the group A 
 
Intraperitoneal glucose tolerance test (IPGTT) 
The result of IPGTT is depicted in fig. 3. Following intraperitoneal 
glucose load (2 g/kg body weight), Group B exhibited significant 
reduction of FBG level at (29%) 2 h and (32%) 4 h and Group C 
exhibited significant reduction of FBG level at (35%) 2 h and (33%) 
4 h in comparison with the Group A. The significant reduction of FBG 
level was observed at (23%) 1 h, (33%) 2 h, and (39%) 4 h in Group 
D whereas Group E exhibited more improved glucose tolerance than 
other groups with significant reduction of FBG level at (22%) 0.5 h, 
(36%) 1 h, (52%) 2 h, and (61%) 4 h in comparison with the Group 
A in the study. As illustrated in fig. 4, the computed values of AUGTC 
(t0–t4) of (1076.88±7.67) Group B, (992.63±8.07) Group C, 
(1012.71±8.91) Group D, and (612.21±14.98) Group E were 
significantly (p<0.001) different from (1377.75±14.57) Group A in 
the study.  
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Fig. 3: Result of IPGTT of different experimental groups. The 
values represent the mean±SEM; n = 6 
 
 
Fig. 4: The area under the glucose tolerance curves [AUGTC (t0–
t4)] of control as well as treated groups. The values represent 
the mean±SEM; n = 6. Significant differences: ***p<0.001 as 
compared with the group A 
 
Biochemical analysis 
The result of GHb% test is depicted in fig. 5. The result 
demonstrated that GHb% level was increased significantly in 
(18.43±0.58) Group B as compared with the Group A whereas 
significant decrease of GHb% level was observed in (15.02±0.88) 
Group C and (14.23±0.53) Group D as compared with the Group B in 
the study.  
The result of lipid profile test is demonstrated by table 1. As shown 
in the table, there was significant difference of total cholesterol, 
triglyceride, HDL-C, LDL-C, and VLDL-C level in Group B as 
compared with the Group A in the study. 
 
 
Fig. 5: Result of the GHb% level of different experimental 
groups. The values represent the mean±SEM; n = 6. Significant 
differences: ###p<0.001 as compared with the group A and 
**p<0.01 as compared with the group B 
 
However, the total cholesterol, LDL-C, HDL-C, VLDL-C, and 
triglyceride levels in Group C as well as Group D were found 
significantly different from the Group B in the study. The computed 
values of AI are also shown in table 1. The AI value was significantly 
high in Group B as compared with the Group A but Group C and 
Group D showed significantly less value of AI in comparison with the 
Group B in the study. 
  
Table 1: Lipid profile test and AI values of different experimental groups 
Groups Total  cholesterol (mg/dl) Triglyceride (mg/dl) HDL-C (mg/dl) LDL-C (mg/dl) VLDL-C (mg/dl) AI 
Group A 117±7.10 99.60±6.05 73.40±4.88 23.68±2.93 19.92±1.21 1.60±0.04 
Group B 189.40±10.78### 169.80±13.06### 29.20±1.46### 126.24±9.60### 33.96±2.61### 6.60±0.62### 
Group C 127.40±6.20***  114.80±4.64** 67.20±2.22*** 37.24±5.08*** 22.96±0.93** 1.90±0.09*** 
Group D 119.20±2.13*** 104.80±2.08*** 70.40±0.93*** 27.84±2.42*** 20.96±0.42*** 1.70±0.04*** 
The values represent the mean±SEM; n = 6. Significant differences: ###p<0.001 as compared with the Group A and **p<0.01, ***p<0.001 as 
compared with the group B. 
 
DISCUSSION 
STZ or N-(methyl nitro carbamoyl)–D-glucosamine is a well 
reported diabetogenic agent produces mild to severe types of 
diabetes depending on the route of administration [17]. STZ is a 
cytotoxic glucose analog which transports through low-affinity 
GLUT2 transporter into β-cell and causes cell damage through 
various mechanisms [18-20]. Insulin deficiency due to β-cell damage 
causes increased production of glucose by the liver and decrease 
utilization of glucose in peripheral tissues [21]. Therefore, 
administration of STZ in mice showed a significant increase in blood 
glucose with a concomitant increase of cholesterol and triglyceride 
level in the study.  
In acute antihyperglycemic study, FBG level was reduced in a dose 
dependent manner showing both 50 mg/kg bw and 100 mg/kg bw 
doses of CHL were quite effective in reduction of blood glucose level 
in diabetic mice. Similarly, dose dependent decrease of FBG level 
was also noted in the sub-acute study where 50 mg/kg bw dose was 
able to reduce FBG at same significance level of 100 mg/kg bw dose 
on 21 d and 28 d in diabetic mice. Therefor 50 mg/kg bw dose of 
CHL was considered as the optimum dose instead of 100 mg/kg bw 
dose and used for the further study.  
Glucose tolerance test is a diagnostic method to detect pre-diabetic 
conditions and also used to evaluate blood glucose homeostasis in 
diabetic patients. In IPGTT, CHL and other standard drugs showed a 
significant effect on glucose tolerance in diabetic mice however the 
most pronounced effect was observed in the case of insulin. In CHL 
administered group, the pattern of glucose clearance from blood was 
quite similar with the biguanide drug metformin, which acts through 
enhancing insulin action and absorption of glucose in peripheral 
tissues and inhibits gluconeogenesis. The other drug glibenclamide 
used in our study is a sulfonylurea derivative, which functional 
mechanisms include stimulation of pancreatic β-cells to release 
more insulin and inhibition of glucagon secretion. Therefore, the 
functional mechanism of CHL in lowering blood glucose can be 
predicted as similar to the mechanism of metformin’s action. The 
AUGTC (t0–t4) was computed to summarize IPGTT and represent a 
single index value. The AUGTC (t0–t4) value of CHL administered 
group showed a significant difference from AUGTC (t0–t4) value of 
STZ induced diabetic mice.  
Patar et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 293-296 
296 
In diabetes mellitus, the glycosylated hemoglobin is formed by non-
enzymatic reaction of excess glucose with hemoglobin and the rate 
of its formation is directly proportional to blood glucose level. 
Therefore, it is considered as a well-established parameter to check 
glycemic control during diabetes [22]. It is noted in our present 
study that GHb% was produced significantly in diabetic mice 
suggesting glycosylation of hemoglobin due to hyperglycemia. In 
contrast to diabetic mice, glycosylated hemoglobin was reduced 
significantly in CHL administered mice suggesting less available of 
glucose for glycosylation of hemoglobin in the blood.  
Cholesterol and triglyceride levels are often increased during 
diabetes and triggers risk of atherosclerosis and coronary heart 
disease in diabetic patients [23]. Our data were in line with the 
notion that STZ induced diabetic mice exhibited clear-cut 
abnormalities in lipid metabolism as evidenced from the significant 
elevation of plasma total cholesterol, triglycerides, LDL-C, VLDL-C, 
AI and reduction of HDL-C levels. Treatment with CHL for 28 d 
significantly reduced total cholesterol, triglyceride, LDL-C, and 
VLDL-C associated with a concomitant significant increase in HDL-C 
level and a decrease in AI in diabetic mice indicating its potent 
antihyperlipidemic activity. Several studies have exhibited that 
decrease in LDL-C along with an increase in HDL-C level is 
associated with the low possibility of coronary heart disease. 
Therefore, CHL treatment has also the potential to reduce 
atherosclerosis and cardiac risk in diabetic mice.  
CONCLUSION 
In conclusion, it can be stated from our findings that CHL has both 
the antihyperglycemic and antihyperlipidemic effects in STZ induced 
diabetic mice. However, the exact mechanism(s) of CHL behind these 
effects was not fully elaborated by this study and further 
investigative work is underway.  
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